Recordati Industria Chimica E Farmaceutica (RCDTF) Stock Price, News & Analysis

Company Overview

Recordati Industria Chimica e Farmaceutica S.p.A. is an Italy-based pharmaceutical company focused on the research, development, manufacture and commercialization of prescription medicines. Its business is centered on specialty-care and rare-disease treatments, as well as selected products for primary care and other therapeutic areas.

The company’s portfolio includes medicines for conditions such as endocrine disorders, cardiovascular disease, central nervous system disorders and rare diseases. Recordati markets both proprietary products and established branded medicines, including treatments based on active ingredients such as osilodrostat, cariprazine and lercanidipine. Its rare-disease operations expanded through the acquisition of EUSA Pharma, which added products for specialized and orphan indications.

Founded in Italy in 1926 by Giovanni Recordati, the company has developed from a domestic pharmaceutical business into an international group. Recordati serves healthcare markets across Europe and in other regions, including the United States and selected countries in the Middle East, North Africa and Latin America. The group is headquartered in Milan, Italy, and is led by Chief Executive Officer Rob Koremans, with Andrea Recordati serving as chairman.

Key Stats

• Today's Range: $58.00 to $58.00
• 50-Day Range: $58.00 to $58.00
• 52-Week Range: $55.88 to $60.00
• Volume: N/A
• Average Volume: 1 shs
• Market Capitalization: $11.97 billion
• P/E Ratio: 20.68
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Recordati Industria Chimica E Farmaceutica Stock Analysis - MarketRank™

Recordati Industria Chimica E Farmaceutica scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Recordati Industria Chimica E Farmaceutica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Recordati Industria Chimica E Farmaceutica has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Recordati Industria Chimica E Farmaceutica is 20.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Recordati Industria Chimica E Farmaceutica is 20.68, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.66.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of Recordati Industria Chimica E Farmaceutica has been sold short.

Short Interest Ratio / Days to Cover

Recordati Industria Chimica E Farmaceutica has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Recordati Industria Chimica E Farmaceutica has recently decreased by 24.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Recordati Industria Chimica E Farmaceutica does not currently pay a dividend.

Dividend Growth

Recordati Industria Chimica E Farmaceutica does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Recordati Industria Chimica E Farmaceutica this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Recordati Industria Chimica E Farmaceutica insiders have not sold or bought any company stock.

Percentage Held by Institutions

Recordati Industria Chimica E Farmaceutica has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:RCDTF
• Previous Symbol: NASDAQ:RCDTF
• CIK: N/A
• Web: www.recordati.com
• Phone: 390-248-7871
• Fax: 39-02-4007-3747
• Employees: 4,693
• Year Founded: 1926

Profitability

• EPS (Trailing Twelve Months): $2.80
• Trailing P/E Ratio: 20.68
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $501.92 million
• Net Margins: 18.38%
• Pretax Margin: 22.20%
• Return on Equity: 33.73%
• Return on Assets: 12.76%

Debt

• Debt-to-Equity Ratio: 0.79
• Current Ratio: 1.26
• Quick Ratio: 0.86

Sales & Book Value

• Annual Sales: $2.96 billion
• Price / Sales: 4.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 206,300,000
• Free Float: N/A
• Market Cap: $11.97 billion
• Optionable: Not Optionable
• Beta: 0.25